AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock h

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the com

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribe

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announce

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst pri

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 re

AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced a

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering

Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and

AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Mode

AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/

AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for m

Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul

AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experi

BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained

AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-6

Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 por

Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe

BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portugu

AbCellera ‌said Monday its experimental menopause treatment significantly reduced the ​frequency and

Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDA

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises t

Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Over

AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks C

AbCellera Biologics NASDAQ: ABCL said it expects to report top-line data “very soon” from its Phase

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the an

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2026 Business Results.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Verte

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCel

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy an

Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in po

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the anal

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL)

AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 porti

Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL

AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 202